[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-other\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-other":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054000","factors-affecting-post-transplant-cyclophosphamide-ptcy-efficacy-100054000",false,"NCT03555851","Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy","Elucidation of Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide (PTCy) as a Strategy for Graft Versus Host Disease Prevention in Haploidentical, Matched Related Donor and Matched Unrelated Donor Peripheral Blood Hematopoietic Cell Transplantation","Inclusion Criteria\n\nRecipients and donors must meet all of the following applicable inclusion criteria to participate in this study:\n\n1. Informed consent and HIPAA authorization for release of personal health information signed by the subject.\n2. Age ≥ 18 years at the time of consent.\n3. Subject is scheduled as a recipient or respective donor (Donor consent\u002Fparticipation is not required for subjects undergoing matched unrelated donor HCT) for the following hematopoietic stem cell transplants (HCT) procedures using a non-myeloablative regimen at Levine Cancer Institute (LCI), and has been deemed a qualified candidate by his\u002Fher physician, per LCI medical standards: haplo-identical donor HCT, match related donor (MRD) HCT, matched unrelated donor (MUD) HCT.\n4. Recipient only: Planned post-transplant cyclophosphamide\n5. As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria\n\nSubjects meeting any of the criteria below may not participate in the study:\n\n1. Recipient only (applies only to haplo-identical and MRD HCT recipients; not required for MUD HCT recipients): Does not have a respective donor who is willing to sign informed consent for participation in this study.\n2. Recipient only: Treatment with any investigational drug within 30 days prior to day -6 of treatment\n3. Donor only (applies only to haplo-identical and MRD HCTs; donor participation is not required for MUD HCTs): Does not have a respective recipient who is willing to sign informed consent for participation in this study.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).",[24,25],"Leukemia, Not Otherwise Specified","Leukemia, Other","RECRUITING","2026-07-10",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2018-07-13",{"date":34,"type":20},"2035-08",{"name":36,"class":37},"Wake Forest University Health Sciences","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100252131","hairy-cell-leukemia-patient-data-registry-100252131","NCT02560883","Hairy Cell Leukemia Patient Data Registry","Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia","HCL-PDR","Inclusion:\n\n* Patients with classic hairy cell leukemia\n* Patients with the variant of hairy cell leukemia.\n\nExclusion:\n\n* Children are excluded from the study, since Hairy Cell Leukemia wasn't described in children.",{"count":48,"type":20},5000,"The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and\u002For mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in partnership with investigators from its Centers of Excellence, seeks to develop a registry to help researchers identify new trends in outcomes, recognize the most effective treatments, discover previously unknown complications of the disease, and design clinical trials for new therapies.",[25],[52],"Hairy Cell","2026-06-30",{"date":55,"type":30},"2026-07-02",{"date":57,"type":30},"2013-01-02",{"date":59,"type":20},"2030-12-31",{"name":61,"class":37},"Ohio State University Comprehensive Cancer Center",8,{"id":64,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":66,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":71,"leadSponsor":72,"locationsCount":38},"100328413",{"count":19,"type":20},[24,25],"2026-01-06",{"date":69,"type":30},"2026-01-08",{"date":32,"type":30},{"date":34,"type":20},{"name":36,"class":37}]